News

FDA panel addresses risks of power morcellators in fibroid surgery

Publish date: July 11, 2014

 

References

Dr. Sobolewski disclosed being a consultant and speaker for Covidien, and is a consultant for and holds stock options in TransEnterix. (Neither company has morcellation products; Covidien manufactures specimen retrieval bags.) None of the panel members has relevant disclosures.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Retroperitoneal exploration extends survival in stage IIIc ovarian cancer
MDedge Hematology and Oncology
Surgical fellowship directors: General surgery trainees arrive ill prepared
MDedge Hematology and Oncology
Routine bilateral salpingectomy with hysterectomy gains acceptance
MDedge Hematology and Oncology
MammoSite has comparatively high long-term complication rate
MDedge Hematology and Oncology
Race, ethnicity influence chances of minimally invasive hysterectomy
MDedge Hematology and Oncology
Laparoscopic radical trachelectomy preserves fertility potential
MDedge Hematology and Oncology
Surgery may benefit elderly women with endometrial cancer
MDedge Hematology and Oncology
Gene panel identifies residual neuroblastoma metastases
MDedge Hematology and Oncology
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge Hematology and Oncology
Study suggests robotics have altered hysterectomy landscape
MDedge Hematology and Oncology

Related Articles